1. Home
  2. FOLD vs HSAI Comparison

FOLD vs HSAI Comparison

Compare FOLD & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • HSAI
  • Stock Information
  • Founded
  • FOLD 2002
  • HSAI 2014
  • Country
  • FOLD United States
  • HSAI China
  • Employees
  • FOLD N/A
  • HSAI N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • HSAI
  • Sector
  • FOLD Health Care
  • HSAI
  • Exchange
  • FOLD Nasdaq
  • HSAI Nasdaq
  • Market Cap
  • FOLD 2.5B
  • HSAI 2.8B
  • IPO Year
  • FOLD 2007
  • HSAI 2023
  • Fundamental
  • Price
  • FOLD $8.15
  • HSAI $26.98
  • Analyst Decision
  • FOLD Strong Buy
  • HSAI Strong Buy
  • Analyst Count
  • FOLD 9
  • HSAI 4
  • Target Price
  • FOLD $26.44
  • HSAI $31.58
  • AVG Volume (30 Days)
  • FOLD 5.8M
  • HSAI 3.0M
  • Earning Date
  • FOLD 11-05-2025
  • HSAI 11-24-2025
  • Dividend Yield
  • FOLD N/A
  • HSAI N/A
  • EPS Growth
  • FOLD N/A
  • HSAI N/A
  • EPS
  • FOLD N/A
  • HSAI 0.11
  • Revenue
  • FOLD $571,160,000.00
  • HSAI $347,701,639.00
  • Revenue This Year
  • FOLD $20.98
  • HSAI $61.81
  • Revenue Next Year
  • FOLD $20.74
  • HSAI $45.70
  • P/E Ratio
  • FOLD N/A
  • HSAI $252.08
  • Revenue Growth
  • FOLD 25.35
  • HSAI 36.51
  • 52 Week Low
  • FOLD $5.51
  • HSAI $4.02
  • 52 Week High
  • FOLD $12.65
  • HSAI $30.85
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 56.40
  • HSAI 48.64
  • Support Level
  • FOLD $7.69
  • HSAI $26.89
  • Resistance Level
  • FOLD $8.59
  • HSAI $28.69
  • Average True Range (ATR)
  • FOLD 0.37
  • HSAI 1.20
  • MACD
  • FOLD -0.05
  • HSAI -0.46
  • Stochastic Oscillator
  • FOLD 54.44
  • HSAI 8.67

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

About HSAI Hesai Group each ADS represents one Class B ordinary share

Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.

Share on Social Networks: